Literature DB >> 6358978

Bromocriptine and premenstrual symptoms: a survey of double blind trials.

B Andersch.   

Abstract

This is a survey of 14 placebo-controlled studies regarding the treatment of premenstrual symptoms with bromocriptine. There is no substantial support that bromocriptine is an effective drug in the premenstrual syndrome as an entity. Symptoms such as irritability, depression, and anxiety were not significantly improved during treatment with bromocriptine compared to placebo treatment. Bromocriptine appears to be the treatment of choice in premenstrual mastodynia if the dosage of bromocriptine is at least 5 mg daily. Bromocriptine may therefore have a place in selected cases of the premenstrual syndrome with associated mastodynia.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6358978     DOI: 10.1097/00006254-198311000-00001

Source DB:  PubMed          Journal:  Obstet Gynecol Surv        ISSN: 0029-7828            Impact factor:   2.347


  6 in total

1.  Premenstrual dysphoric disorder: burden of illness and treatment update.

Authors:  Teri Pearlstein; Meir Steiner
Journal:  J Psychiatry Neurosci       Date:  2008-07       Impact factor: 6.186

2.  Premenstrual syndrome. Evidence-based treatment in family practice.

Authors:  Sue Douglas
Journal:  Can Fam Physician       Date:  2002-11       Impact factor: 3.275

Review 3.  Premenstrual syndrome and premenstrual dysphoric disorder: guidelines for management.

Authors:  M Steiner
Journal:  J Psychiatry Neurosci       Date:  2000-11       Impact factor: 6.186

4.  Premenstrual symptoms: another look.

Authors:  N F Woods
Journal:  Public Health Rep       Date:  1987 Jul-Aug       Impact factor: 2.792

Review 5.  Update on research and treatment of premenstrual dysphoric disorder.

Authors:  Joanne Cunningham; Kimberly Ann Yonkers; Shaughn O'Brien; Elias Eriksson
Journal:  Harv Rev Psychiatry       Date:  2009       Impact factor: 3.732

6.  Premenstrual syndrome.

Authors:  Kimberly Ann Yonkers; P M Shaughn O'Brien; Elias Eriksson
Journal:  Lancet       Date:  2008-04-05       Impact factor: 79.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.